Efficacy and Safety Study of Pegylated Interferon Lambda-1a With Ribavirin and Daclatasvir, to Treat naïve Subjects With Chronic HCV Genotypes 1, 2, 3, and 4 Who Are Co-infected With HIV

Stopped Sponsor decision not based on any new unexpected safety findings or efficacy observations.

Conditions

• Chronic Hepatitis C Infection

Interventions

• BIOLOGICAL: Pegylated Interferon Lambda-1a
• DRUG: Daclatasvir (DCV)
• DRUG: Ribasphere (RBV)

Sponsor

Bristol-Myers Squibb